Literature DB >> 19535442

Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells.

Michael L Vetter1, Richard T D'Aquila.   

Abstract

Cytoplasmic APOBEC3G has been reported to block wild-type human immunodeficiency virus type 1 (HIV-1) infection in some primary cells. It is not known whether cytoplasmic APOBEC3G has residual activity in activated T cells, even though virion-packaged APOBEC3G does restrict HIV-1 in activated T cells. Because we found that APOBEC3G expression is greater in activated CD4(+) T-helper type 1 (Th1) lymphocytes than in T-helper type 2 (Th2) lymphocytes, we hypothesized that residual target cell restriction of incoming Vif-positive virions that lack APOBEC3G, if present, would be greater in Th1 than Th2 lymphocytes. Infection of activated Th1 cells with APOBEC3-negative virions did result in decreased amounts of early and late reverse transcription products and integrated virus relative to infection of activated Th2 cells. Two-long terminal repeat (2-LTR) circles, which are formed in the nucleus when reverse transcripts do not integrate, were increased after APOBEC3-negative virus infection of activated Th1 cells relative to infection of activated Th2 cells. In contrast, 2-LTR circle forms were decreased after infection of APOBEC3G-negative cells with APOBEC3G-containing virions relative to APOBEC3G-negative virions and with Th1 cell-produced virions relative to Th2 cell-produced virions. Increasing APOBEC3G in Th2 cells and decreasing APOBEC3G in Th1 cells modulated the target cell phenotypes, indicating causation by APOBEC3G. The comparison between activated Th1 and Th2 cells indicates that cytoplasmic APOBEC3G in activated Th1 cells partially restricts reverse transcription and integration of incoming Vif-positive, APOBEC3G-negative HIV-1. The differing effects of cytoplasmic and virion-packaged APOBEC3G on 2-LTR circle formation indicate a difference in their antiviral mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535442      PMCID: PMC2738200          DOI: 10.1128/JVI.00020-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Authors:  Qin Yu; Renate König; Satish Pillai; Kristopher Chiles; Mary Kearney; Sarah Palmer; Douglas Richman; John M Coffin; Nathaniel R Landau
Journal:  Nat Struct Mol Biol       Date:  2004-04-18       Impact factor: 15.369

3.  APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.

Authors:  Cécile Esnault; Odile Heidmann; Frédéric Delebecque; Marie Dewannieux; David Ribet; Allan J Hance; Thierry Heidmann; Olivier Schwartz
Journal:  Nature       Date:  2005-01-27       Impact factor: 49.962

Review 4.  The expanding universe of T-cell subsets: Th1, Th2 and more.

Authors:  T R Mosmann; S Sad
Journal:  Immunol Today       Date:  1996-03

Review 5.  Cytokines induce the development of functionally heterogeneous T helper cell subsets.

Authors:  A O'Garra
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

Review 6.  Functional diversity of helper T lymphocytes.

Authors:  A K Abbas; K M Murphy; A Sher
Journal:  Nature       Date:  1996-10-31       Impact factor: 49.962

7.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Authors:  Ya-Lin Chiu; Vanessa B Soros; Jason F Kreisberg; Kim Stopak; Wes Yonemoto; Warner C Greene
Journal:  Nature       Date:  2005-04-13       Impact factor: 49.962

8.  Productive and lytic infection of human CD4+ type 1 helper T cells with macrophage-tropic human immunodeficiency virus type 1.

Authors:  Y Tanaka; Y Koyanagi; R Tanaka; Y Kumazawa; T Nishimura; N Yamamoto
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

9.  Increased in vitro replication of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates in Th2 lymphocytes may correlate with AIDS progression.

Authors:  Harold Ofori; Paweł P Jagodziński
Journal:  Scand J Infect Dis       Date:  2004

10.  Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.

Authors:  D Unutmaz; V N KewalRamani; S Marmon; D R Littman
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  18 in total

1.  APOBEC3G complexes decrease human immunodeficiency virus type 1 production.

Authors:  Kenneth L Martin; Megan Johnson; Richard T D'Aquila
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  APOBEC3G: a double agent in defense.

Authors:  Harold C Smith
Journal:  Trends Biochem Sci       Date:  2011-01-14       Impact factor: 13.807

3.  The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3.

Authors:  Angelo Kolokithas; Kyle Rosenke; Frank Malik; Duncan Hendrick; Lukas Swanson; Mario L Santiago; John L Portis; Kim J Hasenkrug; Leonard H Evans
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

4.  Inhibition of LINE-1 and Alu retrotransposition by exosomes encapsidating APOBEC3G and APOBEC3F.

Authors:  Atanu K Khatua; Harry E Taylor; James E K Hildreth; Waldemar Popik
Journal:  Virology       Date:  2010-02-11       Impact factor: 3.616

5.  A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif.

Authors:  Shivender M D Shandilya; Markus-Frederik Bohn; Celia A Schiffer
Journal:  Virology       Date:  2014-10-29       Impact factor: 3.616

Review 6.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Authors:  Jessica L Smith; Wei Bu; Ryan C Burdick; Vinay K Pathak
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

7.  APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription.

Authors:  Alyssa L MacMillan; Rahul M Kohli; Susan R Ross
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

8.  Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex.

Authors:  Spyridon Stavrou; Takayuki Nitta; Swathi Kotla; Dat Ha; Kunio Nagashima; Alan R Rein; Hung Fan; Susan R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

9.  Human regulatory T cells are targets for human immunodeficiency Virus (HIV) infection, and their susceptibility differs depending on the HIV type 1 strain.

Authors:  Maria E Moreno-Fernandez; Wildeman Zapata; Jason T Blackard; Genoveffa Franchini; Claire A Chougnet
Journal:  J Virol       Date:  2009-10-14       Impact factor: 5.103

Review 10.  APOBEC3 Proteins in Viral Immunity.

Authors:  Spyridon Stavrou; Susan R Ross
Journal:  J Immunol       Date:  2015-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.